Related Experiment Video

Updated: Jun 13, 2026

Revealing the Ferroptotic Phenotype of Medulloblastoma
04:01

Revealing the Ferroptotic Phenotype of Medulloblastoma

Published on: March 15, 2024

Recent therapeutic advances for treating medulloblastoma: focus on new molecular targets

A L Schmidt1, A L Brunetto, G Schwartsmann

  • 1Center for Biotechnology, Federal University of Rio Grande do Sul, 91501-970 Porto Alegre, RS, Brazil.

CNS & Neurological Disorders Drug Targets
|May 5, 2010
PubMed

Insights

New therapeutics are crucial for treating pediatric medulloblastoma, the most common pediatric brain tumor. This review focuses on novel molecular targets and translational studies to improve survival rates and reduce treatment toxicity.

Area of Science:

  • Pediatric Oncology
  • Neuro-oncology
  • Molecular Biology

Background:

  • Medulloblastoma is the most common malignant pediatric brain tumor, originating in the cerebellum.
  • Current standard treatments (surgery, radiotherapy, chemotherapy) yield poor survival in young children.
  • Limited radiation doses are used to avoid severe neurocognitive and endocrinologic side effects.

Purpose of the Study:

  • To review recent therapeutic advancements for medulloblastoma.
  • To highlight novel molecular targets for improved treatment strategies.
  • To discuss progress in translational studies for medulloblastoma therapy.

Main Methods:

  • Literature review of recent therapeutics for medulloblastoma.
  • Focus on new molecular targets and their therapeutic implications.
  • Analysis of advances in translational research for medulloblastoma treatment.

Main Results:

  • Standard treatments have limitations in efficacy and toxicity for young patients.
  • Understanding oncogenic pathways is key to developing targeted therapies.
  • Identification of specific molecular targets offers potential for improved outcomes.

Conclusions:

  • New therapeutic strategies targeting molecular pathways are essential for medulloblastoma.
  • Translational studies are vital for advancing treatment options.
  • Improving patient survival while minimizing treatment toxicity is a primary goal.

More Related Videos

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice05:10

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Published on: October 3, 2010

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...